322 related articles for article (PubMed ID: 22826617)
1. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
2. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
3. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
[TBL] [Abstract][Full Text] [Related]
4. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
[No Abstract] [Full Text] [Related]
5. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
[TBL] [Abstract][Full Text] [Related]
9. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.
Deng H; Jiang Q; Yang Y; Zhang S; Ma Y; Xie G; Chen X; Qian Z; Wen Y; Li J; Yang J; Chen L; Zhao X; Wei Y
Cancer Biol Ther; 2011 Feb; 11(4):401-9. PubMed ID: 21150280
[TBL] [Abstract][Full Text] [Related]
10. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
He Z; Wu J; Dang H; Lin H; Zheng H; Zhong D
Cancer Lett; 2011 Apr; 303(2):92-8. PubMed ID: 21330050
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.
Zhang G; Zhang Z; Liu Z
Tumour Biol; 2013 Jun; 34(3):1887-94. PubMed ID: 23494182
[TBL] [Abstract][Full Text] [Related]
13. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
Zhou J; Gao Q; Chen G; Huang X; Lu Y; Li K; Xie D; Zhuang L; Deng J; Ma D
Clin Cancer Res; 2005 Dec; 11(23):8431-40. PubMed ID: 16322306
[TBL] [Abstract][Full Text] [Related]
14. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
Li L; Huang K; Zhao H; Chen B; Ye Q; Yue J
Cell Cycle; 2020 May; 19(10):1236-1252. PubMed ID: 32275843
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
[TBL] [Abstract][Full Text] [Related]
16. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
18. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
[TBL] [Abstract][Full Text] [Related]
20. Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC.
He Z; Deng W; Jiang B; Liu S; Tang M; Liu Y; Zhang J
Gene; 2018 Oct; 673():46-55. PubMed ID: 29913237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
